ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,277.51
0.80%
Dow Jones
38,686.32
1.51%
US Dollar vs MXN
16.99024
-0.30%
Brent Oil
81.295
0.00%
Bitcoin
67,750.25
0.40%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Catalyst Pharmaceuticals Inc (CPRX)

  7. Catalyst Pharmaceuticals Inc (CPRX) Noticias

CPRX Catalyst Pharmaceuticals Inc

16.05
-0.06 (-0.37%)
31 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Catalyst Pharmaceuticals Inc CPRX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-0.06 -0.37% 16.05 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
16.30 16.03 16.48 16.17 16.11
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
31/5/202415:50EDGAR2Form S-8 - Securities to be offered to employees in employee..
31/5/202415:47EDGAR2Form POS EX - Post-effective amendment adding exhibits to..
31/5/202415:46EDGAR2Form POS EX - Post-effective amendment adding exhibits to..
31/5/202415:43EDGAR2Form POS EX - Post-effective amendment adding exhibits to..
30/5/202415:43EDGAR2Form 8-K - Current report
30/5/202412:41GLOBECatalyst Pharmaceuticals Receives U.S. FDA Approval For..
28/5/202407:03GLOBECatalyst Pharmaceuticals to Participate at the Jefferies..
21/5/202416:28EDGAR2Form 8-K - Current report
08/5/202415:54EDGAR2Form 8-K - Current report
08/5/202415:16GLOBECatalyst Pharmaceuticals Reports Solid First Quarter 2024..
08/5/202415:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/5/202407:00GLOBECatalyst Pharmaceuticals to Participate at the BofA..
22/4/202407:00GLOBECatalyst Pharmaceuticals to Report First Quarter 2024..
28/3/202407:03GLOBECatalyst Pharmaceuticals Announces Support for the Inaugural..
27/3/202407:03GLOBECatalyst Pharmaceuticals to Participate in the 2024 Cantor..
13/3/202406:55GLOBECatalyst Pharmaceuticals Announces AGAMREE® Now Commercially..
05/3/202407:03GLOBECatalyst Pharmaceuticals to Participate at the Barclays 26th..
28/2/202417:03GLOBECatalyst Pharmaceuticals Reports Strong Fourth Quarter and..
27/2/202407:03GLOBECatalyst Pharmaceuticals to Present at MDA Clinical &..
21/2/202408:00GLOBECatalyst Pharmaceuticals Announces Publication of Santhera..
16/2/202416:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202416:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202416:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202416:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202416:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202416:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202416:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202407:03GLOBECatalyst Pharmaceuticals to Report Fourth Quarter and..
09/1/202416:15EDGAR2Form 8-K - Current report
09/1/202415:05GLOBECatalyst Pharmaceuticals, Inc. Announces Closing of Public..
08/1/202407:10EDGAR2Form 8-K - Current report
05/1/202416:23EDGAR2Form 8-K - Current report
05/1/202416:15EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
05/1/202407:02GLOBECatalyst Pharmaceuticals, Inc. Announces Pricing of Public..
04/1/202415:49GLOBECatalyst Pharmaceuticals, Inc. Announces Proposed Public..
03/1/202416:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202416:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202416:18EDGAR2Form 3 - Initial statement of beneficial ownership of..
29/12/202316:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/12/202316:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/12/202316:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/12/202316:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/12/202316:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/12/202316:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/12/202316:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/12/202316:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/12/202316:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/12/202315:30EDGAR2Form 8-K - Current report
18/12/202305:30GLOBECatalyst Pharmaceuticals Announces FIRDAPSE® New Drug..
15/12/202312:47EDGAR2Form 144 - Report of proposed sale of securities

Su Consulta Reciente

NASDAQ
CPRX
Catalyst Pharmaceuticals
DGFX
FLETABTC
Fleta Token
BIT
UB4Q5T
Unicredit Bank
NASDAQI
JIVE
JPMorgan International V...
GDAX
LINKEUR
ChainLink Token
COIN
XPROBTC
LSE
77OU
Rep Ghana 61a
GDAX
VGXEUR
Voyager
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados